ClinicalTrials.gg
Not yet recruitingNCT07652320Updated Jun 22, 2026

Glycaemic Response of Arabic Bread

An interventional study of Control Bread and Chickpea-Enriched Arabic Bread in Overweight, Obesity and Glycaemic Response, sponsored by University of Nottingham. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-22.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Nottingham · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Obesity by University of Nottingham — 5 open to participants now, 5 under way, none of them phase 3. Obesity · University of Nottingham.

Planned enrollment
11th of 17
14 · median 24
Started
2026
with 1 other
No phase
15 of 21
4 open now
Registered
21st of 21
by date

Among the 21 studies in Obesity by University of Nottingham, this one is the 11th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2026, is one of 15 with no phase, and was the 21st registered.

Obesity

11,556 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 21 studies in Obesity by University of Nottingham are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Obesity by University of Nottingham, or all of them as a file.
02

Study summary

Bread remains one of the most widely consumed staple foods worldwide, with wheat flour serving as its traditional foundation. However, the widespread dependence on refined wheat-based bread has paralleled the rising prevalence of type 2 diabetes (T2D), partly owing to its high glycaemic index (GI), which results in rapid increases in blood glucose levels. Enhancing the nutritional quality of bread, therefore, represents an important target for dietary intervention.

Developing alternative flour blends for bread production presents a potential strategy for improving glycaemic control and supporting glucose homeostasis. Accordingly, this clinical trial aims to determine whether the partial replacement of wheat flour with legume flours, including chickpea, pea, and lentil, in Arabic bread formulations can lower glycaemic responses compared with traditional Arabic wheat bread.

Read the detailed description

This study will be a crossover trial. Participants living with overweight and obesity will be recruited and fully informed about the study before giving informed consent. Eligible participants will attend the University of Nottingham on 4 separate visits following an overnight fast of at least 10 hours. On each visit, participants will consume one of three Arabic bread formulations or a control, with a one-week washout between visits. Each bread sample will provide an equivalent of 50 g of available carbohydrate:

  1. Control bread (100% wheat flour)
  2. Arabic bread containing 30% chickpea flour, with 70% wheat flour (primary comparison with control)
  3. Arabic bread containing 30% pea flour, with 70% wheat flour(optional secondary comparison with control)
  4. Arabic bread containing 30% lentil flour, with 70% wheat flour (optional secondary comparison with control)

The primary focus of this study is the comparison between the control bread and the chickpea-enriched bread, as chickpea flour represents the main intervention. The pea-enriched bread and lentil-enriched variants are included as optional secondary comparisons to provide additional insights into the broader effect of legume flour substitution on glycaemic response.

Study Visits:

The procedures for each visit are summarised below:

  1. Pre-visit fast: Participants will fast for at least 10 hours before each visit.
  2. Blood glucose sampling: Capillary blood glucose will be measured via finger prick at baseline and at regular intervals over 120 minutes following consumption (0, 15, 30, 60, 90, and 120 min) of the bread sample to assess the postprandial glycaemic response.
  3. Appetite assessment: Participants will complete visual analogue scale questionnaires at baseline and at set intervals throughout each visit to assess subjective appetite responses.
  4. Sensory evaluation: Participants will be asked to rate the sensory acceptability of each bread sample using a 9-point hedonic scale immediately after consumption.
  5. Dietary intake: Participants will complete 24-hour food diaries in each visit.

Gastrointestinal symptoms will also be monitored via a brief self-reported questionnaire at baseline and post-consumption.

03

Conditions studied

  • Overweight
  • Obesity
  • Glycaemic Response

Browse trials for

Keywords

  • Glycaemic Response
  • Arabic Bread
  • Legume Flour
  • Wheat Flour
  • Postprandial Glucose
  • Overweight
  • Obesity
  • Satiety
  • Appetite
  • Crossover Study
04

In context

Obesity Reclassified

11,556 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 14 is below the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants will be adults living with overweight or obesity ( [BMI] > 25 kg/m²).
  • Participants will be of any gender.
  • Participants will be aged 18 to 65.
  • Participants will be from any sociodemographic background.
  • Participants will be able to provide .
  • Participants will be able to understand spoken and written English and be able to record their responses to questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Those with food allergies or intolerances to any of the study ingredients, including wheat, chickpeas, lentils, or peas, will not be eligible.
  • Individuals with a known diagnosis of metabolic or chronic health conditions, such as diabetes, insulin resistance, hypertension, or phenylketonuria, will be excluded due to the potential impact on glycaemic control and study outcomes.
  • Participants with a fasting blood glucose level of above 7.0 mmol/L.
  • Use of medications that influence blood glucose levels (e.g., , antipsychotics, antiviral protease inhibitors) or substances that interfere with digestion and absorption (such as laxatives or fibre supplements) will result in exclusion.
  • Pregnant or breastfeeding individuals will not be included due to the physiological changes that may influence study outcomes.
  • Participants with implanted medical devices, including pacemakers, artificial organs, defibrillators, or joint replacements, will be excluded for safety considerations.
  • Anyone who has undergone major surgery or hospitalisation within the last 5 months will be deemed ineligible.
  • Individuals who have participated in another research study involving invasive procedures within the last 3 months will be excluded.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Control bread followed by chickpea bread

    Participants will consume control Arabic bread followed by chickpea-enriched Arabic bread after the one week's washout period. Participants who complete the primary crossover phase may optionally continue to pea and/or lentil bread interventions.

    Other: Control Bread · Other: Chickpea-Enriched Arabic Bread · Other: Pea-Enriched Arabic Bread · Other: Lentil-Enriched Arabic Bread

  • Experimental
    Chickpea bread followed by control bread

    Participants will consume chickpea-enriched Arabic bread followed by control Arabic bread after one week the washout period. Participants who complete the primary crossover phase may optionally continue to additional exploratory bread interventions, including pea bread and/or lentil bread.

    Other: Control Bread · Other: Chickpea-Enriched Arabic Bread · Other: Pea-Enriched Arabic Bread · Other: Lentil-Enriched Arabic Bread

Interventions

  • OtherControl Bread

    Arabic bread prepared with 100% wheat flour, providing an equivalent of 50g of available carbohydrate.

  • OtherChickpea-Enriched Arabic Bread

    Arabic bread prepared with 30% chickpea flour and 70% wheat flour, providing an equivalent of 50g available carbohydrate. (This is the primary experimental comparison)

  • OtherPea-Enriched Arabic Bread

    Arabic bread prepared with 30% pea flour and 70% wheat flour, providing an equivalent of 50g available carbohydrate. (Optional secondary comparison)

  • OtherLentil-Enriched Arabic Bread

    Arabic bread prepared with 30% lentil flour and 70% wheat flour, providing an equivalent of 50g available carbohydrate. (Optional secondary comparison)

07

What researchers measure

Primary outcomes

  1. Postprandial Blood Glucose Response

    Differences in the iAUC for capillary blood glucose will be compared between bread formulations.

    Time frame: 120 minutes

Secondary outcomes

  1. Peak Postprandial Capillary Blood Glucose

    Differences in the peak capillary blood glucose value after consuming each bread formulation.

    Time frame: 120 minutes

  2. Appetite Response

    Appetite sensations (hunger, fullness, desire to eat sweet foods, desire to eat salty foods, desire to eat fatty foods, and desire to eat savoury foods) will be assessed using a 100-mm Visual Analogue Scale (VAS). Scores range from 0 to 100 mm. Higher scores indicate greater intensity of the appetite sensation being measured (e.g., greater hunger, fullness, or desire to eat).

    Time frame: 120 minutes

  3. Sensory Acceptability

    Sensory acceptability of each Arabic bread sample will be assessed using a 9-Point Hedonic Scale. Scores range from 1 to 9, with higher scores indicating greater liking and sensory acceptability across sensory attributes, including overall liking, colour, aroma, flavour, texture, chewability, roundness, and crumb characteristics.

    Time frame: Immediately after consumption

  4. 24 hour food intake

    Total energy intake, macronutrient intake until midnight after product consumption.

    Time frame: 24 hours

08

Study locations

1 site
  • School of Biosciences, University of Nottingham, Sutton Bonington Campus, United Kingdom
    Nottingham, United Kingdom
    • Simon Welham, Associate Professor · Contactsimon.welham@nottingham.ac.uk · 0115 951 6129
    • Wejdan Shamakhay, PhD Student · Contactalyws7@nottingham.ac.uk
    • Wejdan Shamakhay, PhD student · Principal investigator
    • Simon Welham, Associate Professor · Principal investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Mar 2027, 9 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 9 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2026
First posted
Jun 17, 2026
StartEst.
Jun 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07652320
Responsible party
Wejdan Shamakhay (Principal Investigator, University of Nottingham) — Principal investigator
First posted
Jun 17, 2026
Start date
Jun 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jun 22, 2026

Study contacts

Wejdan Shamakhay, Phd Student
Contact
alyws7@nottingham.ac.uk
+44
Simon Welham, Associate Professor
Contact
simon.welham@nottingham.ac.uk

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion